Bottom line
Is FBTAX a good fund? The bottom line
FBTAX is the Class A share class of Fidelity Advisor Biotechnology Fund, a managed technology sector mutual fund from Fidelity.
Its expense ratio is 0.94% — about $94 a year on every $10,000 invested, more expensive than 65% of technology sector funds we track.
It returned +31.5% over one year, +6.4% a year over five years, +7.7% a year over ten (as of Sep 30, 2026, per its prospectus).
With $2.2 billion in net assets and 129 holdings, its largest position is Abbvie Inc (14.7%) and the top 10 make up 46.9% of the portfolio.
What to watch
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What FBTAX invests in
Fidelity Advisor Biotechnology Fund seeks capital appreciation.
Normally investing primarily in common stocks. Normally investing at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. These companies may include, for example, companies engaged in the research, development, manufacturing, or marketing of products based in whole or in part on genetic analysis and genetic engineering. Fidelity may consider a company to be principally engaged in the designated business activity or activities based on: (i) the level of a company's assets, income, sales, or profits that are committed to, derived from, or related to the designated business activity or activities, or (ii) whether a third party has given the company an…
From the fund's prospectus (filed Sep 24, 2026).
FBTAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FBTAX | +31.5% | +6.4% | +7.7% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Sep 30, 2026
What FBTAX costs
On a $10,000 investment, FBTAX's 0.94% expense ratio costs about $94 a year. The prospectus estimates $1,663 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
FBTAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Abbvie Inc | 14.71% |
| 2 | Gilead Sciences Inc | 5.70% |
| 3 | Spyre Therapeutics Inc | 3.83% |
| 4 | Alnylam Pharmaceuticals Inc | 3.62% |
| 5 | Dianthus Therapeutics Inc | 3.55% |
| 6 | Cogent Biosciences Inc | 3.25% |
| 7 | Oruka Therapeutics Inc | 3.24% |
| 8 | Insmed Inc | 3.05% |
| 9 | Revolution Medicines Inc | 3.00% |
| 10 | Argenx Se | 3.00% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 46.9% of the fund. See all top 25 holdings and asset mix →